FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average by	urden
hours por rosponso	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	1 1	-,														
(Print or Type Responses) 1. Name and Address of Reporting Person* LYONS GARY A				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner				
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/20/2011							-	Officer (giv	ve title below)	Other	(specify below)	
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(Cit	y)	(State)	(Zip)			Ta	ble I	- Non-Deri	vative Se	curitie	s Acquir	ed, Disposed	of, or Bene	eficially Owned	ı	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea		2A. Deeme Execution I any (Month/Day		e, if C	(Instr. 8)		4. Securities Acq (A) or Disposed of (Instr. 3, 4 and 5)		of (D) Owned Follow		ing Reporte	d O Fo	wnership orm: Be irect (D) Ov	Nature Indirect eneficial wnership astr. 4)		
							Code	e V A	mount	(A) or (D)	Price	ce		(I	nstr. 4)	
								in this	form are	not re	equired	collection to respond	unless the		u SEC 14	74 (9-02)
			Table II -					in this display	form are s a curr osed of, o	e not re ently v	equired valid ON ficially (to respond IB control r	unless the		u SEC 14	74 (9-02)
Security	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transac Code	tion of Se or of (Ir	, warr Numb	er ative es d (A) sed	in this display	form are s a curre osed of, o nvertible ercisable a Date	e not recently were Bene e securi	equired valid ON ficially (ities)	to respond MB control r Dwned and Amount orlying es	unless the number.		10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indirec Beneficia
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion of Se Acor of (In an	Numb Deriva curitie equired Dispo (D) astr. 3,	er ative es d (A) sed 4,	in this display	form are s a curre osed of, o nvertible recisable a Date y/Year)	e not recently versions and	ficially (tites) 7. Title of Under Securities	to respond MB control r Dwned and Amount orlying es	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indirec Beneficia Ownershi

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
LYONS GARY A C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/Dolly Vance (Attorney-in-Fact)	05/20/2011
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly for twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.